Gameto Highlights Late-Stage Fertility Trial and ARPA-H–Backed Menopause Program at ASRM Meeting

Gameto has shared an update. The company reported an active presence at the American Society for Reproductive Medicine (ASRM) Annual Meeting in San Antonio, where it highlighted progress across its fertility and menopause programs. Gameto’s Chief Scientific Officer presented an oral abstract on the Ameno program, which is developing a next-generation, hormone-responsive ovarian implant intended to improve menopause care. Additional booth presentations detailed the scientific basis, clinical potential, and ARPA-H–funded research associated with Ameno. The company also spotlighted its Phase 3 Fertilo clinical trial through a clinician-led discussion featuring its Chief Medical Officer and an external fertility specialist, and conducted training sessions for physicians using an egg retrieval simulator to support trial execution.

For investors, Gameto’s activities signal continued advancement of its clinical pipeline in both menopause and fertility, two large and growing segments of the reproductive health market. The presence of a Phase 3 trial suggests the Fertilo program is in late-stage development, which, if successful, could accelerate the path toward potential commercialization and future revenue generation, subject to regulatory outcomes. The ARPA-H funding associated with the Ameno program underscores third-party validation and may help support R&D efforts while reducing capital burden. Engagement with key opinion leaders and practicing clinicians at ASRM could enhance future adoption prospects and inform trial design and real-world positioning. Overall, the update reinforces Gameto’s strategic focus on building a differentiated portfolio in reproductive medicine and may strengthen its competitive standing ahead of key clinical readouts.